Pathway Genomics welcomed strategic partner IBM Watson to its customer base in a round that lifted its overall funding to more than $130m.

Healthcare reimbursement data platform Aver took its total funding to almost $25m in a round featuring Hearst and existing investor General Electric.

The antibody-based drug developer has raised $77m in financing, with Merck leading its $30m series B round in 2014.

The oncology platform provider, previously backed by Alphabet and LabCorp, has secured $175m in a round led by strategic partner Roche.

Millendo has received series B funding from investors including Roche, while AstraZeneca acquired a stake in the biopharmaceutical company through a licensing deal.

The Google Ventures-backed genome editing technology company has raised $163m in equity across two rounds.

Novo and Roche-backed Corvus has raised more than $108m in venture funding in just over a year and will spend the IPO proceeds on developiing its immuno-oncology therapies.

Taiyu Capital, a corporate venturing unit of TigerMed, is among the investors in a round that increased the concussion response specialist's total funding to $13m.

Novan, which is planning to move its acne drug candidate into phase 3 trials next year, raised $50m in a Malin Corporation-backed round in March.

Sheffield University spinout Diurnal began trading on Aim, on Christmas eve, raising $44.6m.